INTERNEURON DEXFENFLURAMINE OBESITY THERAPY NEEDS DATA ON NEUROLOGIC DAMAGE & CO-MORBIDITIES; ADVISORY CMTE. DIFFERS ON LONG-TERM SAFETY AND EFFICACY
Executive Summary
Interneuron's long-term obesity therapy dexfenfluramine (Redux) needs more data on co-morbidities and the potential for neurologic damage from the drug, FDA's Endocrinologic & Metabolic Drugs Advisory Committee determined Sept. 28.